JP2020515286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515286A5 JP2020515286A5 JP2019567512A JP2019567512A JP2020515286A5 JP 2020515286 A5 JP2020515286 A5 JP 2020515286A5 JP 2019567512 A JP2019567512 A JP 2019567512A JP 2019567512 A JP2019567512 A JP 2019567512A JP 2020515286 A5 JP2020515286 A5 JP 2020515286A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cancer
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 46
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 3
- 102000002068 Glycopeptides Human genes 0.000 claims description 3
- 108010015899 Glycopeptides Proteins 0.000 claims description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 230000003302 anti-idiotype Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 206010033645 Pancreatitis Diseases 0.000 claims 3
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 102000047627 human CEACAM5 Human genes 0.000 claims 1
- 102000046810 human CEACAM6 Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 28
- 102000036639 antigens Human genes 0.000 description 28
- 108091007433 antigens Proteins 0.000 description 28
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 24
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762463868P | 2017-02-27 | 2017-02-27 | |
| US62/463,868 | 2017-02-27 | ||
| PCT/US2018/020050 WO2018157169A1 (en) | 2017-02-27 | 2018-02-27 | Antibody constructs and methods of treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515286A JP2020515286A (ja) | 2020-05-28 |
| JP2020515286A5 true JP2020515286A5 (OSRAM) | 2022-01-04 |
| JP7325045B2 JP7325045B2 (ja) | 2023-08-14 |
Family
ID=63254387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567512A Active JP7325045B2 (ja) | 2017-02-27 | 2018-02-27 | 癌を処置する抗体コンストラクトおよび方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11623953B2 (OSRAM) |
| EP (1) | EP3585819A4 (OSRAM) |
| JP (1) | JP7325045B2 (OSRAM) |
| CN (1) | CN111148760A (OSRAM) |
| CA (1) | CA3092434A1 (OSRAM) |
| WO (1) | WO2018157169A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118234748A (zh) * | 2021-05-19 | 2024-06-21 | 精密生物制品股份有限公司 | 用于治疗血液恶性肿瘤的方法和组合物 |
| WO2024091848A2 (en) * | 2022-10-25 | 2024-05-02 | The Trustees Of The University Of Pennsylvania | Anti-ceacam6 car-t cells for the treatment of ceacam6+ tumors |
| WO2025006562A1 (en) * | 2023-06-27 | 2025-01-02 | Bio4T2, Llc | Methods of car administration and treatment |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| AU2002246668A1 (en) * | 2000-11-02 | 2002-07-30 | Molecular Discoveries, L.L.C. | Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc) |
| JP4694128B2 (ja) | 2002-01-30 | 2011-06-08 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法 |
| KR20060089732A (ko) | 2003-10-03 | 2006-08-09 | 브라이엄 앤드 위민즈 하스피틀 | Ｔｉｍ-3 리간드 및 그의 방법 |
| JP2008537551A (ja) | 2005-03-31 | 2008-09-18 | カランド ファーマシューティカルズ， インコーポレイテッド | リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用 |
| CN101607985B (zh) * | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体，包含其的组合物，及其用途 |
| CA2813133C (en) * | 2010-10-01 | 2023-10-31 | National Research Council Of Canada | Anti-ceacam6 antibodies and uses thereof |
| CN103421113B (zh) * | 2012-05-22 | 2018-01-19 | 武汉华鑫康源生物医药有限公司 | 抗BLyS抗体 |
| SG10201913324PA (en) * | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| EP3628688A1 (en) * | 2015-03-23 | 2020-04-01 | Bayer Pharma Aktiengesellschaft | Anti-ceacam6 antibodies and uses thereof |
-
2018
- 2018-02-27 WO PCT/US2018/020050 patent/WO2018157169A1/en not_active Ceased
- 2018-02-27 CN CN201880027595.6A patent/CN111148760A/zh active Pending
- 2018-02-27 US US16/489,038 patent/US11623953B2/en active Active
- 2018-02-27 JP JP2019567512A patent/JP7325045B2/ja active Active
- 2018-02-27 CA CA3092434A patent/CA3092434A1/en active Pending
- 2018-02-27 EP EP18758526.0A patent/EP3585819A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| JP2020534830A5 (OSRAM) | ||
| JP6239503B2 (ja) | 新規な抗ｃｘｃｒ４抗体並びに癌の検出および診断のためのその使用 | |
| RU2018124602A (ru) | Новые анти-pd-l1 антитела | |
| CN112574307A (zh) | 抗人Claudin18.2抗体及其应用 | |
| JP2019527553A5 (OSRAM) | ||
| KR102661060B1 (ko) | 항인간 IgG4 모노클로날 항체, 및 그 항체를 이용한 인간 IgG4 측정 시약 | |
| JP2021500916A5 (OSRAM) | ||
| KR20130012132A (ko) | 암의 치료를 위한 인간화 항-cxcr4 항체들 | |
| JP2017538439A5 (OSRAM) | ||
| CN113227148B (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| CN112094348B (zh) | 抗人Tim3抗体或其功能性片段及其应用 | |
| JP2020515286A5 (OSRAM) | ||
| JPWO2022256563A5 (OSRAM) | ||
| JPWO2019217145A5 (OSRAM) | ||
| CN114957468A (zh) | 一种抗Siglec15抗体及其用途 | |
| KR102350259B1 (ko) | Igf-1r 항체 및 암의 진단을 위한 그의 용도 | |
| CN116003615A (zh) | 一种抗卡利普多的单克隆抗体及其应用 | |
| CN105683755B (zh) | 陷阱分子和检测分子的用途及其相关试剂盒和组合物 | |
| JPWO2023107558A5 (OSRAM) | ||
| WO2022074648A1 (en) | Marker for response to pd-1/pd-l1 immunotherapy | |
| CN116836291B (zh) | 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用 | |
| TWI869740B (zh) | 一種體外檢測ｓＴＮＦＲ２蛋白濃度的方法及其檢測試劑和檢測試劑盒 | |
| US20190194319A1 (en) | Anti-ascl1 antibodies and methods of use | |
| WO2018213680A1 (en) | Diagnostic antibodies and methods of use |